GSK announces succession plan for leadership of Consumer Healthcare business

GSK announces succession plan for leadership of Consumer Healthcare business
- Emma Walmsley appointed President, Consumer Healthcare Europe and President Designate, Worldwide Consumer Healthcare

Issued:  Monday 22 March 2010, London UK

GlaxoSmithKline plc (GSK) today announced that Emma Walmsley has been appointed President, Consumer Healthcare Europe, and President Designate, Worldwide Consumer Healthcare, effective 1 May 2010.

Emma joins GSK from L'Oreal where she has been the leader of their Consumer Products business in China. Previously, Emma was based in New York where she had global responsibility for the mass-market Maybelline cosmetics business.

 As President, Consumer Healthcare Europe, Emma will have operational responsibility for GSK's European business and brands, succeeding Manfred Scheske. Within two years, global leadership for the Consumer Healthcare business will pass from John Clarke, President, Worldwide Consumer Healthcare, to Emma.

 Andrew Witty, Chief Executive Officer, GlaxoSmithKline, said:  "Under John's leadership, Consumer Healthcare has become a key element in GSK's strategy to deliver sustainable financial performance. Emma's appointment comes at an important time as we seek to diversify and further grow this business. It is also continued evidence of our approach to maintain leadership excellence at GSK through proactive succession planning."

 John Clarke, President, Worldwide Consumer Healthcare said: "In just under three years, Emma has greatly accelerated the growth in L'Oreal's China consumer business. She has a strong track record and experience in FMCG marketing in both established and emerging markets. She joins us from a company which, like ours, has a strong scientific research base and I look forward to working closely with her over the next two years."
 
GlaxoSmithKline Enquiries:
 
 
 
UK Media enquiries:
 Philip Thomson
 (020) 8047 5502
 
 
 Claire Brough
 (020) 8047 5502
 
 
 Stephen Rea
 (020) 8047 5502
 
 
 Alexandra Harrison
 (020) 8047 5502
 
 
 Jo Revill
 (020) 8047 5502
 
 
  
  
 
US Media enquiries:
 Nancy Pekarek
 (919) 483 2839
 
 
 Mary Anne Rhyne
 (919) 483 2839
 
 
 Kevin Colgan
 (919) 483 2839
 
 
 Sarah Alspach
 (919) 483 2839
 
 
 
 
 
European Analyst/Investor enquiries:
 David Mawdsley
 (020) 8047 5564
 
 
 Sally Ferguson
 (020) 8047 5543
 
 
 Gary Davies
 (020) 8047 5503
 
 
 
 
 
US Analyst/ Investor enquiries:
 Tom Curry
 (215) 751 5419
 
 
 Jen Hill Baxter
 (215) 751 7002
 

Suggested Articles

I-MAB's anti-GM-CSF drug works "upstream" in inflammation pathways, potentially blocking several dangerous cytokines in COVID-19, executives…

Antibe's lead drug beat placebo at reducing osteoarthritis pain, boosting its case as an alternative to NSAIDs, commonly used to treat the condition.

The trial marks the start of a new phase of the response to SARS-CoV-2 in which people will receive drugs designed specifically for the virus.